View in EDS

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer

Saved in:
Bibliographic Details
Title: Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
Authors: L. C. Hanker, A. El-Balat, Z. Drosos, S. Kommoss, T. Karn, U. Holtrich, G. Gitas, M. Graeser-Mayer, M. Anglesio, D. Huntsman, A. Rody, H. Gevensleben, F. Hoellen
Source: J Cancer Res Clin Oncol
Publisher Information: Springer Science and Business Media LLC, 2021.
Publication Year: 2021
Subject Terms: Adult, Aged, 80 and over, Carcinoma, Ovarian Epithelial/mortality [MeSH], Female [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Original Article – Cancer Research, Adult [MeSH], Ovarian cancer, Humans [MeSH], Progression-Free Survival [MeSH], Middle Aged [MeSH], Prognosis, Carcinoma, Ovarian Epithelial/metabolism [MeSH], Biomarkers, Tumor/metabolism [MeSH], Prognosis [MeSH], Young Adult [MeSH], SPHK1, Immunohistochemistry/methods [MeSH], Phosphotransferases (Alcohol Group Acceptor)/metabolism [MeSH], Carcinoma, Ovarian Epithelial, Middle Aged, Immunohistochemistry, Progression-Free Survival, 3. Good health, Phosphotransferases (Alcohol Group Acceptor), Young Adult, 03 medical and health sciences, 0302 clinical medicine, Biomarkers, Tumor, Humans, Female, Aged
Description: Purpose Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.
Document Type: Article
Other literature type
Language: English
ISSN: 1432-1335
0171-5216
DOI: 10.1007/s00432-021-03558-x
Access URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03558-x.pdf
https://pubmed.ncbi.nlm.nih.gov/33660008
https://link.springer.com/article/10.1007/s00432-021-03558-x
https://www.ncbi.nlm.nih.gov/pubmed/33660008
https://link.springer.com/content/pdf/10.1007/s00432-021-03558-x.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021516
https://pubmed.ncbi.nlm.nih.gov/33660008/
https://europepmc.org/article/MED/33660008
https://repository.publisso.de/resource/frl:6449928
Rights: CC BY
Accession Number: edsair.doi.dedup.....fcbc840b0249181e56bdb93370d0c86a
Database: OpenAIRE
Description
Abstract:Purpose Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.
ISSN:14321335
01715216
DOI:10.1007/s00432-021-03558-x